Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deflazacort Extension Study in DMD
NCT02295748Phase 1Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Dec 2014
- Primary completion
- Aug 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deflazacort in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc. Primary endpoint: Number, frequency, and severity of adverse events at 3 years. Started Dec 2014; status: completed.
02
Drugs
deflazacort
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02295748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02295748.